Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC

NCT06132698 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

17

Enrollment

OTHER

Sponsor class

Conditions

NSCLC Associated With Leptomeningeal Metastases

Interventions

DRUG: Tislelizumab or pembrolizumab, pemetrexed

Sponsor

West China Hospital